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Abstract
Mutations in penicillin-binding protein 2 (PBP 2) encoded by mosaic penA alleles are critical for
intermediate resistance to the expanded-spectrum cephalosporins ceftriaxone and cefixime in
Neisseria gonorrhoeae. Three of the ~60 mutations present in mosaic alleles of penA, G545S,
I312M, and V316T, have been reported to be responsible for increased resistance, especially to
cefixime (Takahata et al. 2006. Antimicrob Agents Chemother 50:3638-45). However, we
observed that the minimum inhibitory concentrations (MICs) of penicillin, ceftriaxone, and
cefixime for a wild type strain (FA19) containing a penA gene with these three mutations
increased only 1.5-, 1.5-, and 3.5-fold, respectively. In contrast, when these three mutations in a
mosaic penA allele (penA35) were reverted back to wild type and the gene transformed into FA19,
the MICs of the three antibiotics were reduced to near wild type levels. Thus, these three
mutations display epistasis, in that their capacity to increase resistance to β-lactam antibiotics is
dependent on the presence of other mutations in the mosaic alleles. We also identified an
additional mutation, N512Y, that contributes to decreased susceptibility to expanded-spectrum
cephalosporins. Finally, we investigated the effects of a mutation (A501V) currently found only in
non-mosaic penA alleles on decreased susceptibility to ceftriaxone and cefixime, under the
expectation that this mutation may arise in mosaic alleles. Transfer of the mosaic penA35 allele
containing an A501V mutation into FA6140, a chromosomally mediated penicillin-resistant
isolate, increased the MICs of ceftriaxone (0.4 μg/ml) and cefixime (1.2μg/ml) to levels above
their respective breakpoints. The proposed structural mechanisms of these mutations are discussed
in light of the recently published structure of PBP 2.
Neisseria gonorrhoeae is the etiologic agent of the sexually transmitted infection gonorrhea.
In 2007, there were over 350,000 infections reported in the United States (1). Gonococcal
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infections are often asymptomatic, especially in females, and if left untreated can cause
pelvic inflammatory disease and disseminated infections, as well as contribute to the spread
of the disease. Because of the lack of a vaccine, antibiotics are the primary treatment for
gonococcal infections.
Traditionally, gonorrhea was treated with penicillin G, but in 1986 this antibiotic was
discontinued in the USA due to the onset of resistance. For the same reason, tetracyclines
were also withdrawn. More recently, high-level resistance to fluoroquinolones led to the
withdrawal of these antibiotics from the recommended list in the USA, leaving only
expanded-spectrum cephalosporins such as ceftriaxone and cefixime as reliable treatments
for gonococcal infections (2). Importantly, strains with decreased susceptibility to these
antibiotics (also called cephI strains) are becoming widespread in the community (3,4),
making it crucial that we understand the mechanisms that lead to cephI resistance so that
new antibiotics and new approaches be found for treating gonococcal infections before we
are left with no effective antibiotics (4). This need is highlighted by recent reports of
treatment failures using oral expanded-spectrum cephalosporins in Japan and Hong Kong
(5,6), as well as two confirmed treatment failures of pharyngeal gonococcal infections with
ceftriaxone (7), although the latter two cases probably reflect the well-recognized difficulties
in eradicating pharyngeal gonorrhea (4).
The most common mechanism of penicillin resistance in N. gonorrhoeae, termed
chromosomally mediated resistance, involves at least 5 resistance determinants (8,9). These
determinants, which are mutated forms of normal genes/loci, can be transferred from a high-
level resistant donor to a susceptible strain by homologous recombination and selection,
with transfer occurring in a defined order (8,10,11). The first step is transfer of penA, which
encodes altered forms of penicillin-binding protein 2 (PBP 2), the lethal target of penicillin
G in N. gonorrhoeae (12). The second determinant transferred is mtrR, which leads to
increased efflux pump expression and activity (13). The third determinant transferred is
penB, which encodes altered forms of the major outer membrane porin, PorB1B (14,15). The
final steps, which result in high-level penicillin resistance, include acquisition of ponA,
encoding an altered form of PBP 1, and a resistance determinant whose identity is unknown
(8). The sum effect of these determinants is to increase the minimum inhibitory
concentration (MIC) of penicillin by 400-fold (from 0.01 μg/ml to 4 μg/ml).
The major difference between penicillin-resistant and cephI strains is the presence of mosaic
penA alleles that encode PBP 2 variants containing up to 60 amino acid changes compared
to PBP 2 from wild type strains. We and others have proposed that the rapid emergence of
cephI strains has occurred by horizontal transfer of mosaic penA genes, which were
generated by recombination events between N. gonorrhoeae and commensal Neisseria
species, into chromosomally mediated penicillin-resistant strains already harboring the
necessary determinants to increase resistance to intermediate levels (16,17).
Takahata et al. have reported that three mutations in mosaic variants of PBP 2, G545S,
I312M, and V316T, are responsible for decreased susceptibility to cefixime (18). However,
when we incorporated these mutations into a wild type penA gene and transformed the gene
into FA19, resistance to penicillin, ceftriaxone, and cefixime increased only marginally (≤ 3-
fold), putting the original conclusion in doubt (see Results). Therefore, we set out to identify
important regions of PBP 2, and amino acids within them, that confer resistance to penicillin
and expanded-spectrum cephalosporins. Our data indicate that more complex and subtle
mechanisms are at play; that is, mosaic PBP 2 variants display epistasis, in which the three
residues identified by Takahata et al. (18)are important in decreasing the rate of acylation,
but only in the presence of other residues that have little to no apparent effect on their own.
We also find that if an A501V mutation, which has been observed recently in non-mosaic
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penA alleles (19–21), were to emerge in mosaic penA alleles, the MICs of ceftriaxone and
ceftriaxone would increase to above the established break points of resistance.
MATERIALS AND METHODS
Strains and Plasmids
The strains and plasmids used in this study are shown in Table 1. FA19 is a penicillin- and
cephalosporin-susceptible strain that served as the recipient strain for most of the studies
described herein (22). In the experiments examining the effect of the A501V mutation,
FA6140, a penicillin-resistant, cephalosporin-susceptible strain (23) that contains all of the
known resistance determinants (i.e., penA, mtrR, penB, and ponA)as well as the unknown
determinant, also served as a recipient strain. pUC18us-penA and pUC18us-penA35 contain
the wild type penA gene from FA19 and the mosaic penA gene from the cephI strain 35/02
(24), respectively, along with 300 bp of downstream sequence and an uptake sequence to
facilitate homologous recombination. To construct the different chimeric PBPs, silent
restriction sites were introduced into the coding sequences of pUC18us-penA and pUC18us-
penA35 by the QuikChange method (Stratagene, Carlsbad, CA). These sites allowed us to
swap out individual cassettes from penA35 with the corresponding cassettes from penA to
create the “−mod” constructs (Fig. 1,Supplemental Fig. 1). Other point mutations were
introduced into the appropriate constructs by overlap extension PCR (25). All constructs
were verified by sequencing before proceeding with transformation experiments.
Transformation
Transformation of the chimeric and mutant constructs into FA19 and FA6140 was
accomplished as described previously (8). Transformants were selected on GCB plates
containing various amounts of antibiotics just above their respective MICs. To verify correct
recombination, transformants were passaged on GCB plates, and the next day, colonies were
boiled in 30 μl water, spun briefly to pellet cell debris, and the supernatants were used as
templates in PCR with the appropriate penA primers. PCR products were sequenced by the
UNC sequencing facility or by Eton Bioscience Inc. (Research Triangle Park, NC).
MIC measurements
The MICs for penicillin, ceftriaxone, and cefixime were determined exactly as described
previously (16). The antibiotics were tested in ~1.5-fold increments to increase the accuracy
of the MIC determination. At least two (and often up to 4) colonies from each
transformation were tested, each verified by PCR amplification and sequencing as described
above. At least three independent MIC experiments were carried out, and the MICs reported
represent the averages of all experiments. Error bars indicate the standard deviation of the
determinations.
Purification of PBP 2 variants
PBP 2, PBP 235/02, and PBP 235/02-A501V were purified as described previously (26).
Briefly, the genes encoding each variant were cloned into derivative of pMAL-C2 (New
England Biolabs, Beverly, MA), pMAL-C2KV, which fuses His6-maltose-binding protein
and an intervening tobacco etch virus (TEV) protease site to amino acid 44 of PBP 2, and
the proteins were expressed in E. coli. The fusion proteins were purified on a Ni2+-NTA
column (GE Healthcare, Piscataway, NJ), cleaved with His6-tagged tobacco etch virus
(TEV) protease, and the digests were re-chromatographed over a Ni2+-NTA column. The
purified proteins were eluted in buffer containing 15 mM imidazole, while uncleaved
protein, His6-TEV andHis6-maltose-binding protein were eluted with 250 mM imidazole.
Tomberg et al. Page 3













The proteins were dialyzed to remove imidazole, concentrated to ~ 6 mg/ml, and frozen at
−80°C.
k2/KS measurements of the rate of acylation by β-lactam antibiotics
The reaction of β-lactam antibiotics with PBP 2 is denoted by the following equation:
, where E•S is the non-covalent enzyme-antibiotic
complex, E-S’ is the acyl-enzyme complex, and P the hydrolyzed antibiotic. k2/Ks constants,
which are a direct measure of the ability of an antibiotic to inhibit a PBP (27), were
calculated from first order rates of acylation of purified, soluble PBP 2 variants by
[14C]penicillin G (Moravek, Brea, CA) as previously described (26,28). Graphs of PBP 2-
[14C]penicillin G complex formation versus time were obtained by incubating 27 μg of
protein with 1.0 μM [14C]penicillin G, and aliquots of ~4 μg were removed at 15 sec
intervals, precipitated with 5% trichloroacetic acid, filtered over Whatman GC-A filters, and
the filters were submitted to scintillation counting. The concentration of [14C]penicillin G
was increased to 25 and 50 μM for determination of k2/KS values with PBP 235/02 and PBP
235/02-A501V, respectively. The k2/Ks values of non-radioactive cephalosporin antibiotics
were obtained in competition experiments with [14C]penicillin G using the following
equation: , where [penG] is the concentration of
[14C]penicillin G used in the reaction and [ceph]0.5 is the concentration of cephalosporin
antibiotic that inhibits the binding of [14C]penicillin G by 50% (27).
RESULTS
Analysis of mosaic PBP 2 mutations I312M, V316T, and G545S in cephI resistance
following incorporation into a wild-type penA background
Takahata et al. reported that three amino acid mutations found in mosaic PBP 2 variants,
I312M, V316T and G545S, are responsible for decreased susceptibility to cefixime in N.
gonorrhoeae (18). To confirm these data, we introduced a single mutation (G545S), a
double mutation (I312M/V316T), or all three mutations (G545S/I312M/V316T) into the
wild type penA gene from FA19, and used these plasmids to transform FA19 to increased
penicillin G or cefixime resistance. No transformants could be isolated with either the single
or double mutants, presumably because they did not confer an increase in resistance.
However, we were able to select for transformants harboring the triple mutant, but the MICs
of penicillin, ceftriaxone, and cefixime for these transformants increased by only 1.5-, 1.5-,
and 3.5-fold, respectively, compared to 12-, 20-, and 100-fold increases, respectively, with
the full penA35 gene (16). Thus, it appears that together these three mutations confer only
minimal increases in resistance to these antibiotics when incorporated into the penA gene
from FA19.
Construction and analysis of PBP 2 chimeras
These data indicated that the mechanisms leading to emergence of cephI strains are more
complex than originally reported, and thus we constructed chimeras between wild type and
mosaic penA genes to identify the regions and amino acids that are important in decreasing
the rate of acylation by the these antibiotics. As shown in Fig. 1, six regions in penA35
bounded by silent restriction sites, termed “modules” and denoted mod0 through mod5,
were replaced by their corresponding modules from penA, and vice versa, and these
constructs were used to transform FA19 to increased cefixime or penicillin resistance. Each
module contained between 3 and 15 amino acid changes, with mod0 comprising the entire
N-terminal domain of PBP 2 and mods 1–5 covering the C-terminal transpeptidase/β-
lactam-binding domain (Figs. 1, S1). No transformants could be selected when individual
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penA35 modules were transferred into wild type penA in an attempt to show gain-of-
function, indicating that no single region contained changes that were capable of conferring
increased resistance to the antibiotics.
In contrast, we were able to select for transformants of FA19 with penA35 constructs in
which individual mosaic penA35 modules were replaced with their wild type counterpart in
penA (Fig. 2). In all cases, the penA35/penA chimeras resulted in lower levels of resistance
relative to penA35, and except for a few instances, the MICs of the three antibiotics
(compared to penA35) decreased similarly for each chimera. For clarity, the different
chimeric constructs are defined in terms of the fold decrease in MIC compared to that
conferred by penA35.
Replacing modules 0 or 2 of penA35 with wild type modules had little to no effect on the
MICs of the three antibiotics, while replacing modules 1, 3 or 4 of penA35 with the
corresponding wild type module decreased MICs from 2- to 3-fold compared to penA35
(Fig. 2). Replacing modules 1 or 4 of penA35 resulted in a greater decrease in the MICs than
replacement of module 3, whereas replacement of modules 3 and 4 together decreased the
MICs of the three antibiotics slightly more than replacement of the individual modules.
Despite repeated attempts, we could not select transformants in which module 5 of penA35
was replaced by wild type, most likely because this chimera did not increase the MIC of
FA19 above that conferred by wild type penA. These data indicate that mutations within
module 5 are the most critical for decreased susceptibility, whereas mutations in modules1
and 4 are important but less so than those in module 5.
Role of G545S and I312M/V316T mutations in cephI resistance
Importantly, modules 1 and 5 contain the I312M/V316T and G545S mutations, respectively,
initially described by Takahata et al. (18). To examine the role of the G545S mutation in
resistance, we incorporated this mutation back into the −mod5 chimera (i.e. −mod5 +
G545S). Unlike the parent −mod5 construct, which did not confer resistance over wild type
levels, the resulting transformants were only slightly less resistant to penicillin and
ceftriaxone compared to those containing the unmodified penA35 gene (Fig. 3),
demonstrating the importance of this mutation. Resistance to cefixime, however, was nearly
3-fold lower, indicating that the G545S mutation is less important for cefixime resistance
and that one or more additional mutations within module 5 appear to be required to reach the
level of penA35. Overall, these data indicated that G545S was the most important mutation
within mod5 for increasing resistance, but the degree to which the mutation is responsible
for resistance depended on the antibiotic being examined.
To examine the role of the I312M and V316T mutations in resistance, we replaced module 1
within the −mod5 + G545S chimera with the wild type sequence of penA (−m1,5 + G545S).
The MICs of all three antibiotics for the resulting transformants decreased by ~2-fold
compared to −mod5 + G545S (Fig. 3). Incorporation of the I312M/V316T double mutation
back into this construct (i.e. −m1,5 + I312M/V316T/G545S) restored the MICs of
ceftriaxone and cefixime in these transformants to the same level as −mod5 + G545S,
whereas the MIC of penicillin did not change. These data suggest that all of the decrease in
the MICs of ceftriaxone and cefixime caused by replacement of module 1 of penA35 with
wild-type sequence was due to the I312M/V316T mutations, while the drop in penicillin
MIC was due to other residue(s) within the module.
Reversion of G545S and I312M/V316T mutations in mosaic penA35
Reversion of the G545S mutation in penA35 back to wild type decreased the MICs of
penicillin, ceftriaxone, and cefixime for the resulting transformants 2-, ~6- and 8-fold,
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respectively, compared to penA35, whereas reversion of the I312M/V316T mutations to
wild type decreased MICs of penicillin, ceftriaxone, and cefixime by 2-, 4- and 4-fold,
respectively. When all three mutations were reverted to wild type, the MICs of penicillin,
ceftriaxone, and cefixime were decreased by 2.5-, 16-, and 25-fold, respectively, relative to
penA35. Importantly, the MICs of ceftriaxone and cefixime for the triple reversion mutant
were nearly identical to that of FA19. These data are consistent with the idea that the three
mutations are important in resistance, but only in the context of some or all of the other 55
mutations found in mosaic penA alleles.
Role of module 4 amino acids in antibiotic resistance
Replacement of module 4 from penA35 with wild type sequence resulted in a ~3-fold
decrease in the MIC of the three antibiotics when the chimera was transformed into FA19
(Fig. 2). This result was intriguing, since module 4 has only three amino acid changes,
F504L, A510V, and N512Y, the first two of which are also found in the non-mosaic penA4
allele from FA6140 (26), a high-level, penicillin-resistant but cephalosporin-susceptible
strain (8,26). These three mutations are clustered on the β3-β4 loop of PBP 2, which is just
C-terminal to the KTG active site motif. We therefore reverted the three changes
individually in penA35 back to the wild type sequence, and determined the MICs of
penicillin, ceftriaxone, and cefixime of the resulting transformants.
Surprisingly, the individual mutations had different effects on the MIC depending on the
antibiotic being examined. For the expanded-spectrum cephalosporins, the most important
reversion was Y512N, which was responsible for most if not all of the decrease in the MICs
observed in strains containing penA35 −mod4. For penicillin, the Y512N mutation had a
minor effect on resistance; instead, both the L504F and V510A reversions decreased
resistance to the same level as the −mod4 construct (Fig. 4). These data highlight the
importance of the β3-β4 loop for the reactivity of β-lactam antibiotics toward PBP 2 and
demonstrate the differential effects of these mutations on the different antibiotics.
Effects of the A501V mutation in PBP 235/02
We also examined the effects of the A501V mutation in both mosaic and non-mosaic penA
genes by incorporating this mutation into the penA4 and penA35 genes and transforming
these genes into FA19 and FA6140 (Fig. 5). When transformed into FA19, the penA4-
A501V and penA35-A501V mutant alleles decreased the MIC of penicillin by 20% and
50%, respectively, compared to levels conferred by the parental alleles (Fig. 5a). In contrast,
penA4-A501V and penA35-A501V both increased ceftriaxone and cefixime MICs between
2-fold and 4-fold above those conferred by penA4 and penA35, respectively. In general, the
effects of the A501V mutation were greater in the penA35 background than in the penA4
background.
Consistent with our results in FA19, when the penA35-A501V gene was transformed into
FA6140, the MIC of penicillin for FA6140 penA35-A501V was nearly half of that for
FA6140 penA35 (Fig. 5b), whereas the MICs of both ceftriaxone and cefixime increased by
over 2-fold. Importantly, the MICs of ceftriaxone and cefixime for the resulting strains, 0.4
and 1.2 μg/ml, respectively, are well above the breakpoints for “resistance” (>0.25 μg/ml for
both antibiotics). These data suggest that emergence of this mutation in mosaic penA genes,
which to date has not occurred, could render both ceftriaxone and cefixime ineffective for
treating gonococcal infections.
k2/Ks constants of wild type PBP 2, PBP 235/02, and PBP 235/02-A501V
To compliment our MIC data, we determined the acylation rate constants of penicillin,
ceftriaxone, and cefixime for purified wild type PBP 2, PBP 235/02, and PBP 235/02-A501V.
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For wild type PBP 2, [14C]penicillin G had a k2/KS of 76,000 M−1s−1, whereas ceftriaxone
and cefixime displayed k2/KS constants that were markedly higher (1.7 × 106 and 1.5 × 106
M−1s−1, respectively; Table 2), consistent with their low MICs for wild type gonococcal
strains. The acylation rates of penicillin G, ceftriaxone, and cefixime for PBP 235/02
decreased 150-to 200-fold compared to wild type, underscoring the marked effect of the
multiple substitutions in mosaic PBP 2 on the kinetics of β-lactam binding. The acylation
rate of penicillin for PBP 235/02-A501V increased ~2.7-fold compared to PBP 235/02, while
the k2/KS of cefixime decreased by 2.3-fold (Table 2). Surprisingly, the rate for ceftriaxone
increased 1.8-fold, opposite of what we expected based on MIC experiments. Except for this
latter result, these data are consistent with the changes observed in strains transformed with
the mosaic penA allele.
Discussion
Takahata et al. reported that three amino acid mutations found in mosaic PBP 2 variants,
I312M, V316T and G545S, are responsible for decreased susceptibility to cefixime in N.
gonorrhoeae (18). In that study, the authors determined the MICs of a range of expanded-
spectrum cephalosporins for transformants of FA1090 harboring penAFA1090 alleles
containing either the G545S mutation alone or G545S together with either the I312M or
V316T mutation (a strain containing all three mutations could not be isolated). The MICs of
ceftriaxone and cefixime increased 2-fold for the G545S transformant and 4-fold and 8-fold,
respectively, for the G545S/I312M or G545S/V316T double transformants. From these data,
the authors concluded that these three mutations were responsible for the decreased MICs
conferredby mosaic penA alleles.
However, when we incorporated the three mutations into the wild type penA allele from
FA19 and transformed it into FA19, the MICs of ceftriaxone and cefixime increased by only
1.5- and 3.5-fold, respectively, well below the levels obtained with the full mosaic penA35
gene (Fig. 2). An important difference between our work and the study by Takahata et al. is
the choice of the parental penA allele. Whereas we used penA from FA19, which we
consider to be a true “wild type” allele (22), Takahata et al. (18) used penA from FA1090,
which contains an Asp345a insertion that decreases the k2/KS acylation rate constant of
penicillin G by 6-fold (26). Presumably, the increased levels of resistance observed by
Takahata et al. were due to the Asp-345a insertion adding to or amplifying the effects of the
mutations. Since the Asp-345a insertion is not present in mosaic penA alleles, the penA gene
from FA1090 is not an optimal background to examine the effects of these mutations.
While the three mutations (I312M, V316T, and G545S) do not increase resistance markedly
when incorporated into a wild type penA gene, they have a striking effect on resistance when
reverted back to the wild type in the mosaic penA35 background, indicating that these
mutations require at least some of the other amino acid changes found in 35/02 to decrease
susceptibility. This phenomenon, referred to as epistasis, has been elegantly described by
Thornton and colleagues (29,30), who identified several “permissive” mutations in steroid
hormone receptors that, while having no functional importance on their own, stabilized
function-switching mutations and facilitated the evolution of new steroid hormone-binding
activity. Weinreich et al., studying the evolution of hydrolytic activity against cefotaxime in
TEM β-lactamase, have described a similar epistatic phenomenon (31). These authors
showed that only a few pathways to full resistance are permissible, since some mutations do
not increase cefotaxime resistance in certain allelic backgrounds. In an example involving
PBPs, Hedge and Spratt (32) defined the steps for acquisition of resistance of E. coli to a
range of cephalosporins through serial mutagenesis of PBP 3 (the functional equivalent of
PBP 2 in N. gonorrhoeae). The authors were able to obtain high-level resistance to
cephalosporins in four steps. Importantly, two of the steps had little effect on resistance, but
Tomberg et al. Page 7













increased protein stability and thermostability of PBP 3 and allowed for subsequent isolation
of resistance-conferring mutations (32).
To suggest how the three mutations described in this study might impact the rate of
acylation, we examined our recent crystal structure of PBP 2from N. gonorrhoeae, solved in
the apo form. G545S, which is the most important mutation for resistance in mosaic penA
alleles, is present at the start of the α11 helix, one of the two helices that pack on top of the 5
anti-parallel β strands typical of penicillin-interacting proteins. The main chain amides of
G545 and G546 are within hydrogen-bonding distance to the side chain hydroxyls of Thr498
and Thr500, respectively, located within the KTG(T) active-site motif (Fig. 6A). By analogy
with other PBPs such as E. coli PBP 5, the main chain amide of Thr500 is predicted to
stabilize the oxyanion hole for the transition state, and so one effect of the G545S mutation
might be to lower acylation by compromising the geometry of the transition state/tetrahedral
intermediate. Alternatively, because the hydroxyl side chains of the equivalent residues to
Thr498 and Thr500 in S. pneumoniae PBP 2x (Ser548 and Thr550) interact with the β-
lactam carboxylate in the covalent complex, alteration of these contacts may be another
mechanism that lowers acylation. Ile312 and Val316 are located on the opposite side of the
helix as Ser310 and Lys313 of the SxxK motif and pack into a hydrophobic pocket (Fig.
6B). Mutation to larger (I312M) or more hydrophilic (V316T) side chains might disrupt
these interactions such that the position of the SxxK motif is altered, leading to decreases in
acylation rates with β-lactam antibiotics. A similar argument has been put forth for the
M339F mutation in S. pneumoniae PBP 2X (33).
In addition to the three mutations discussed above, we also showed that reversion of N512Y
in penA35 decreases resistance to ceftriaxone and cefixime by 2-fold without affecting
penicillin resistance. This result is consistent with its emergence in mosaic penA alleles and
its relative absence in non-mosaic penA alleles found in penicillin-resistant
strains(18,19,21). Asn512 is relatively distant from the active site (Fig. 6B) and the exact
impact of the N512Y mutation on acylation is difficult to predict, but it is located on the β3-
β4 loop that contains mutations that are known to be important for resistance to penicillin in
non-mosaic forms of PBP 2 (26). One possibility is that such a mutation perturbs the
architecture of the KTG motif of β3.
Our work has also highlighted the impending danger of the A501V mutation arising in
mosaic penA alleles, because if it happens this would increase the MICs of ceftriaxone and
cefixime above their breakpoints for resistance. The alteration of A501 in PBP 2 appears to
be a gonococcal-specific alteration, as it has not yet been observed in commensal Neisseria
species, which suggests that it arose through mutation in response to selective pressure with
expanded-spectrum cephalosporins instead of by transformation. Indeed, Takahata et al.
(18)reported the isolation of a spontaneous A501V mutation during transformation
experiments. Thus, it may be a matter of when and not if mutations in Ala501 arise in
mosaic penA genes. Ala501 resides on the β3-β4 loop where mutation of the methyl side
chain to the bulkier side chain of valine could clash with the R1 substituent of the
cephalosporin (Fig. 6B). Consistent with this hypothesis, an A501T mutation, which
introduces a similar branched side chain, affects resistance in a similar manner as A501V
(MU, unpublished observations).
The k2/KS acylation rate constants of the three antibiotics for wild type PBP 2, PBP 235/02
and PBP 235/02-A501V were determined to assess directly the effects of the PBP mutations
on reactivity with β-lactam antibiotics. The k2/KS rate constants for acylation are largely, but
not entirely, consistent with MIC values. For example, acylation rates are dramatically
impaired in PBP 235/02 compared to wild type, with 150-to 200-fold decreases in acylation
rate for all three antibiotics. However, since the MICs increase 10-, 20- and 100-fold for
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penicillin, ceftriaxone, and cefixime, respectively, when penA35 is transformed into FA19, it
is clear that other intrinsic factors, e.g. diffusion through wild type porin channels, likely
play an important role in defining the MIC. One anomaly in the acylation data is the ~2-fold
increase in k2/KS of ceftriaxone for the PBP 235/02-A501V variant, which is inconsistent
with the ~2-fold increase in the MIC for transformants harboring this mutant.
In conclusion, the emergence of decreased susceptibility to expanded-spectrum
cephalosporins through remodeling of the active site of PBP 2 is more complicated than
originally envisioned, with important resistance-conferring mutations showing epistasis. The
acquisition of further mutations, such as A501V, in mosaic penA alleles is likely to increase
resistance to levels that render expanded-spectrum cephalosporins ineffective in treating
gonococcal infections. The need to identify new antibiotics against this organism is therefore
of prime importance in the treatment of STIs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Abbreviations and Textual Footnotes
PBP penicillin-binding protein
MIC minimum inhibitory concentration
cephI cephalosporin-intermediate resistance
NTA nitriloacetic acid
TEV tobacco etch virus
STI sexually transmitted infection
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Fig. 1. Chimeric penA genes used in this study
Silent restriction sites were incorporated into the coding sequences of the penA genes from
FA19 (blue) and 35/02 (green). The modules, designated mod0 through mod5, were used to
create chimeric penA genes in which modules from penA35 were replaced with the
corresponding modules from wild type penA. These chimeric constructs were then used to
create the strains listed in Table 1. The number of amino acid alterations in penA35 relative
to penA for each module is shown below 35/02. The lines represent DNA, and the rectangles
represent the proteins encoded.
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Fig. 2. MICs of penicillin, ceftriaxone, and cefixime for FA19 harboring 3X mutant and chimeric
−mod penA genes
The MICs of penicillin, ceftriaxone, and cefixime for FA19 transformants containing the
indicated 3X mutant (penA-I312M/V316T/G545S) and chimeric (−mod) penA genes (see
Fig. 1 and Table 1) were determined as described in Materials and Methods. The MICs
represent the averages for at least two transformants in a minimum of three independent
experiments, and error bars represent the standard deviation of the values.
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Fig. 3. The G545S and I312M/V316T mutations are critical for conferring resistance to penicillin
and expanded-spectrum cephalosporins only when present in the penA35 background
The contributions of the G545S and I312M/V316T mutations within their respective
modules were probed by either incorporating the mutations in the −mod1, −mod5, and
−mod1,5 chimeric constructs or by reverting the mutations back to wild type in the penA35
gene. The indicated constructs were transformed into FA19 and the MICs of penicillin,
ceftriaxone, and cefixime were determined.
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Fig. 4. MICs of penicillin, ceftriaxone, and cefixime for FA19 harboring penA35 containing
reversion mutations from module 4
FA19 was transformed with the indicated penA35 alleles in which the three mutations in
module 4 (F504L, A510V, and N512Y) were reverted individually back to wild type. The
MICs of penicillin G, ceftriaxone, and cefixime of the resulting transformants were
determined as described in Materials and Methods.
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Fig. 5. MICs of penicillin, ceftriaxone, and cefixime for FA19 and FA6140 harboring the penA4
(from FA6140) or penA35 (from 35/02) allele with or without an A501V mutation
FA19 (A) or FA6140 (B) was transformed with penA4, penA4-A501V, penA35, or penA35-
A501V, and the MICs of penicillin, ceftriaxone, and cefixime for the resulting transformants
were assessed as described in Materials and Methods.
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Fig. 6. Structure of PBP 2 showing the location of important mutations and the active site
sequence motifs
A, Interaction of Thr498 and Thr500 within the KTG(T) active site motif with the main
chain amides of Gly545 and Gly546. Mutation of Gly545 to Ser incorporates a hydroxylated
side chain that potentially could perturb the interactions with the two Thr residues on β3
with the main chain of the α11 helix. B, The crystal structure of apo-PBP 2 from strain
CDC84 of N. gonorrhoeae (2.1Å, unpublished data) was superimposed onto that of S.
pneumoniae PBP 2X in complex with cefuroxime (34) using the SUPERPOSE program of
CCP4 (35). The structure of PBP 2 is from a construct containing the six C-terminal
mutations (but missing the Asp345a insertion) of strain CDC-84 primarily because its β3-β4
loop is more ordered than other PBP 2 structures. In this calculation, the main chain atoms
of 18 residues comprising the three conserved active site motifs superimposed with a root
mean square difference of 0.97Å. Note the proximity of the R1 furyl group of cefuroxime to
the β3 strand nearest to the A501V mutation. The view in this image is from underneath the
α2 helix containing the active site SxxK motif. Also shown are the locations of the I312M,
V316T, and N512Y mutations discussed in the text.
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Table 1
Strains and plasmids used in this study.
Strain or Plasmid Description Reference
Plasmids
pUC18us-penA35* Plasmid containing the penA35 gene from strain 35/02 and an uptake sequence (16) and this study
pUC18us-penA* Plasmid containing the penA gene from strain FA19 and an uptake sequence (16)and this study
pUC18us-penA35*-A501V pUC18us-penA35* harboring an A501V mutation This study
pUC18us-penA4 Plasmid containing the penA4 gene from strain FA6140 and an uptake sequence (16)
pUC18us-penA4-A501V pUC18us-penA4 harboring an A501V mutation This study
Strains
FA19 Penicillin-and cephalosporin-susceptible recipient strain (22)
FA6140 Penicillin-resistant but cephalosporin-susceptible recipient strain (23)
WT-3X FA19 transformed with pUC18us-penA containing I312M, S316V, and G545S
mutations
This study
−mod0, −mod1, etc. FA19 transformed with pUC18us-penA35* in which the indicated module (see
Fig. 1) was replaced with the corresponding module from penA*
This study
−mod5 + G545S FA19 transformed with pUC18us-penA35* in which mod5 was replaced with
corresponding mod5 from wild type; mod5 also contains G545S mutation
This study
−m1,5 + G545S FA19 transformed with pUC18us-penA35* in which mods 1 and 5 were replaced
with corresponding mods from wild type; mod5 also had a G545S mutation
This study
−m1,5 + I312M/V316T/G545S FA19 transformed with pUC18us-penA35* in which mods 1 and 5 were replaced
with corresponding mods from wild type; mod1 additionally had I312M and
V316T mutations and mod5 had a G545S mutation
This study
FA19 penA35-S545G FA19 containing the penA35 gene with reversion of the G545S mutation This study
FA19 penA35-M312I/T316V FA19 containing the penA35 gene with reversion of I312M/V316T mutations This study




Genes contains silent restriction sites incorporated into the coding sequence as depicted in Fig. 1.
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Table 2
k2/KS acylation rates for wild type PBP 2, PBP 235/02, and PBP 235/02-A501V
Proteins were purified and the k2/KS values were determined as described in Materials and Methods. The




Wild Type 75,700 ± 2,300 (7) 1,710,000 ± 90,000 (3) 1,480,000 ± 22,000 (3)
35/02 510 ± 90 (12) 11,300 ± 400 (3) 7,200 ± 300 (4)
35/02-A501V 1,400 ± 140 (6) 20,000 ± 400 (3) 3,100 ± 100 (4)
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